Evidence map›Paper›PMID 31559415›Full record

ArticleInflammatory bowel diseases2020

Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors.

Steffi E M van de Ven, Lauranne A A P Derikx, Iris D Nagtegaal, Carla M van Herpen, Robert P Takes, Willem J G Melchers, Marieke Pierik, Tim van den Heuvel, Rob H A Verhoeven, Frank Hoentjen and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Inflammatory bowel diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Steffi E M van de VenDepartment of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands.
Lauranne A A P DerikxDepartment of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands.
Iris D NagtegaalDepartment of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
Carla M van HerpenDepartment of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Robert P TakesDepartment of Otolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
Willem J G MelchersDepartment of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands.
Marieke PierikDepartment of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Tim van den HeuvelDepartment of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, the Netherlands.
Rob H A VerhoevenDepartment of Research & Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.
Frank HoentjenDepartment of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands.
L H C NissenDepartment of Gastroenterology and Hepatology, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands.
Radboud University Nijmegen · NLMaastricht University Medical Centre · NLErasmus MC · NLJeroen Bosch Ziekenhuis · NLNetherlands Comprehensive Cancer Organisation · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel disease (IBD) patients are at increased risk for developing extra-intestinal malignancies, mainly due to immunosuppressive medication. The risk of developing head and neck cancer in immunosuppressed transplant patients is increased. The relation between IBD patients and laryngeal cancer (LC) remains unclear. We aimed (1) to identify risk factors in IBD patients for LC development and (2) to compare clinical characteristics, outcome, and survival of LC in IBD patients with the general population.

methodsAll IBD patients with LC (1993-2011) were retrospectively identified using the Dutch Pathology Database. We performed 2 case-control studies: (1) to identify risk factors, we compared patients with IBD and LC (cases) with the general IBD population; (2) to analyze LC survival, we compared cases with controls from the general LC population.

resultsWe included 55 cases, 1800 IBD controls, and 2018 LC controls. Cases were more frequently male compared with IBD controls (P < 0.001). For ulcerative colitis (UC), cases were older at IBD diagnosis (P < 0.001). Crohn's disease (CD) cases were more frequently tobacco users (P < 0.001) and more often had stricturing (P = 0.006) and penetrating (P = 0.008) disease. We found no survival difference. Immunosuppressive medication had no impact on survival.

conclusionsMale sex was a risk factor for LC in IBD patients. Older age at IBD diagnosis was a risk factor for UC to develop LC. Tobacco use and stricturing and penetrating disease were risk factors for LC development in CD patients. Inflammatory bowel disease was not associated with impaired survival of LC. Immunosuppressive medication had no influence on survival.

Indexed as

AdultAge FactorsCarcinomaCase-Control StudiesDatabases, FactualFemaleHumansImmunosuppressive AgentsInflammatory Bowel DiseasesLaryngeal NeoplasmsMaleMiddle AgedNetherlandsOutcome Assessment, Health CareRetrospective StudiesRisk FactorsImmunosuppressive Agentshead and neck cancerimmunosuppressive therapyinflammatory bowel diseaseslaryngeal carcinoma

Identifiers

PMID31559415
PMCPMC7301406
OpenAlexW2975209769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.